Background To verify whether serum levels of reactive oxygen metabolites (ROM) are predictive of future clinical remission in patients with rheumatoid arthritis (RA) receiving tocilizumab (TCZ) therapy. Methods A total of 46 patients with RA receiving TCZ therapy were enrolled in this study. Patients were divided into remission and non-remission groups based on disease activity score 28 (DAS28)-erythrocyte sedimentation rate (ESR) or clinical disease activity index (CDAI) at 52 weeks. Associations between serum levels of ROM, C-reactive protein (CRP), and matrix metalloproteinase-3 (MMP-3) at 4 and 12 weeks and the remission by DAS28-ESR and CDAI at 52 weeks were investigated. Results There were no significant differences in CRP and MMP-3 between DAS- or CDAI-remission and non-remission groups at 12 weeks. However, ROM in DAS-remission group were significantly lower than those in the non-remission group. For ROM, the area under the curve of the receiver operating characteristic curve was 0.735 and the cut-off value that distinguished DAS-remission group from non-remission group was 305.5 U. Carr (sensitivity: 70.0%, specificity: 72.2%). A multivariate logistic regression analysis revealed that ROM at 12 weeks was associated with DAS-remission at 52 weeks (odds ratio: 6.067, 95% confidence interval: 1.305-28.203). Conclusion Serum levels of ROM at 12 weeks during TCZ therapy may be predictive of DAS-remission at 52 weeks in patients with RA.

中文翻译：

---

托珠单抗治疗期间 12 周的血清活性氧代谢物水平可预测类风湿性关节炎患者 52 周的疾病活动评分缓解。

背景 验证血清活性氧代谢物 (ROM) 水平是否可预测接受托珠单抗 (TCZ) 治疗的类风湿关节炎 (RA) 患者未来的临床缓解。方法共纳入46例接受TCZ治疗的RA患者。根据52周时的疾病活动评分28（DAS28）-红细胞沉降率（ESR）或临床疾病活动指数（CDAI）将患者分为缓解组和非缓解组。研究了 4 周和 12 周时血清 ROM、C 反应蛋白 (CRP) 和基质金属蛋白酶 3 (MMP-3) 水平与 52 周时 DAS28-ESR 和 CDAI 缓解之间的关联。结果 DAS-或CDAI-缓解组与非缓解组在12周时CRP和MMP-3无显着差异。然而，DAS 缓解组的 ROM 显着低于非缓解组。对于 ROM，受试者工作特征曲线的曲线下面积为 0.735，区分 DAS 缓解组与非缓解组的临界值为 305.5 U.Carr（敏感性：70.0%，特异性：72.2%）。多变量逻辑回归分析显示，12 周时的 ROM 与 52 周时的 DAS 缓解相关（优势比：6.067，95% 置信区间：1.305-28.203）。结论 TCZ 治疗期间 12 周时的血清 ROM 水平可预测 RA 患者 52 周时的 DAS 缓解。735，区分 DAS 缓解组与非缓解组的临界值为 305.5 U. Carr（敏感性：70.0%，特异性：72.2%）。多变量逻辑回归分析显示，12 周时的 ROM 与 52 周时的 DAS 缓解相关（优势比：6.067，95% 置信区间：1.305-28.203）。结论 TCZ 治疗期间 12 周时的血清 ROM 水平可预测 RA 患者 52 周时的 DAS 缓解。735，区分 DAS 缓解组与非缓解组的临界值为 305.5 U. Carr（敏感性：70.0%，特异性：72.2%）。多变量逻辑回归分析显示，12 周时的 ROM 与 52 周时的 DAS 缓解相关（优势比：6.067，95% 置信区间：1.305-28.203）。结论 TCZ 治疗期间 12 周时的血清 ROM 水平可预测 RA 患者 52 周时的 DAS 缓解。